• Characterizing biodistribution to guide target and candidate selection, enabling early identification of on-target engagement and minimizing off-target liabilities
• Quantifying dosimetry through direct and surrogate imaging approaches, improving radionuclide choice and translational accuracy of absorbed dose estimates
• Integrating multimodal imaging to monitor treatment response, accelerating proof-of-mechanism insights and data-driven optimization of therapeutic design

New Company for 2026